Ironvine Capital Partners LLC Has $29.20 Million Stock Position in Danaher Co. (NYSE:DHR)

Ironvine Capital Partners LLC raised its position in Danaher Co. (NYSE:DHR - Free Report) by 23.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 127,225 shares of the conglomerate's stock after purchasing an additional 23,906 shares during the period. Danaher makes up about 3.1% of Ironvine Capital Partners LLC's investment portfolio, making the stock its 16th biggest holding. Ironvine Capital Partners LLC's holdings in Danaher were worth $29,204,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Norges Bank acquired a new stake in Danaher during the 4th quarter worth approximately $2,130,740,000. Raymond James Financial Inc. bought a new stake in shares of Danaher during the fourth quarter worth $391,172,000. Capital World Investors raised its holdings in shares of Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after acquiring an additional 1,566,658 shares during the period. Van ECK Associates Corp lifted its position in Danaher by 6,862.7% in the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate's stock valued at $213,452,000 after acquiring an additional 916,513 shares in the last quarter. Finally, Parnassus Investments LLC increased its holdings in Danaher by 31.8% during the 4th quarter. Parnassus Investments LLC now owns 3,105,388 shares of the conglomerate's stock worth $712,842,000 after purchasing an additional 749,136 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR stock traded down $2.69 during midday trading on Monday, hitting $194.45. 930,468 shares of the company were exchanged, compared to its average volume of 3,345,481. The firm has a market capitalization of $139.16 billion, a P/E ratio of 36.81, a PEG ratio of 2.66 and a beta of 0.86. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a 52 week low of $171.00 and a 52 week high of $281.70. The firm's 50 day moving average price is $200.87 and its two-hundred day moving average price is $223.98.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. As a group, equities research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 25th. Stockholders of record on Friday, March 28th were given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend was Friday, March 28th. This is a boost from Danaher's previous quarterly dividend of $0.27. Danaher's payout ratio is presently 24.85%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DHR. Robert W. Baird dropped their target price on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Wells Fargo & Company cut their price objective on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. The Goldman Sachs Group decreased their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. UBS Group cut their price target on shares of Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Finally, Stifel Nicolaus upgraded Danaher from a "hold" rating to a "buy" rating and set a $260.00 price objective for the company in a report on Friday, March 14th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and an average price target of $264.40.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company's stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 11.10% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.